Keyword Analysis & Research: jco


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
jco0.710.39883853

Keyword Research: People who searched jco also searched

Keyword CPC PCC Volume Score
jco0.821376071
jconsole mbean1.640.353784
jconcepts0.330.9942213
jconsole0.910.7211471
jconline obituaries0.831450780
jcontrol1.470.7291242
jcom0.651962381
jcop1.661960499
jconline1.640.355119
jconnect login0.530.742674
jcop english1.75129291
jconcepts rc1.160.2155758
jcoco1.730.4307674
jcontainers1.740.2879289
jconsole command line0.581500138
jconline lafayette in0.470.7198472
jcog0.90.7562845
jcomic.net1.540.675071
jcombobox20.3420149
jcomic21.970.3736525
jcoin1.830.4304212
jconfig1.140.2994517
jcope0.110.3592615
jconline e edition0.960.3821565
jco precision oncology0.220.8979963

Search Results related to jco on Search Engine

  • Journal of Clinical Oncology | ASCO Publications

    ascopubs.org

    https://ascopubs.org/journal/jco

    WebApr 2, 2024 · A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is …

    DA: 72 PA: 59 MOZ Rank: 14

  • Journal of Clinical Oncology: Vol 42, No 12 - ASCO Publications

    ascopubs.org

    https://ascopubs.org/toc/jco/current

    WebMar 7, 2024 · ORIGINAL REPORTS. Pathologic Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes. Apr 20, 2024. Volume 42 Issue 12. Apr 10, 2024. Volume 42 Issue 11. Apr 1, 2024. Volume 42 Issue 10. Mar 20, 2024.

    DA: 93 PA: 11 MOZ Rank: 84

  • Newest Articles | Journal of Clinical Oncology - ASCO Publications

    ascopubs.org

    https://ascopubs.org/toc/jco/0/0

    WebPACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer. Erica L. Mayer et al. full text abstract pdf Favorite. Cancer Prevention and ...

    DA: 12 PA: 46 MOZ Rank: 8

  • Treatment landscape of triple-negative breast cancer - Nature

    nature.com

    https://www.nature.com/articles/s41571-021-00565-2

    WebNov 9, 2021 · Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype with the least favourable ...

    DA: 6 PA: 29 MOZ Rank: 17

  • Subsequent Breast Cancer in Female Childhood Cancer Survivors ... - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/31075046/

    WebJul 1, 2019 · Purpose: Anthracycline-associated risk for subsequent breast cancer in childhood cancer survivors is hypothesized to be mediated by TP53 mutation-related gene-environment interactions. We characterized treatment/genetic risks and the impact of screening for breast cancer in the St Jude Lifetime Cohort. Patients and methods: …

    DA: 41 PA: 46 MOZ Rank: 9

  • TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab ... - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/33929895/

    WebAug 1, 2021 · Purpose: Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (SG) is a TROP-2 …

    DA: 79 PA: 8 MOZ Rank: 55

  • A phase 2, proof of concept, randomised controlled trial of ... - Nature

    nature.com

    https://www.nature.com/articles/s41467-021-25701-5

    WebSep 17, 2021 · Berberine ursodeoxycholate has been studied for its serum lipid and lipoprotein lowering effects. Here the authors report an 18-week phase 2, randomised, double-blind, placebo-controlled clinical ...

    DA: 7 PA: 11 MOZ Rank: 78

  • Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse

    sciencedirect.com

    https://www.sciencedirect.com/science/article/pii/S2211383522004154

    WebMar 1, 2023 · 1. Introduction. Since the first approval of monoclonal antibody, i.e., rituximab (Rituxan), for cancer therapy in 1997, antibody-based therapy has achieved great success and is now one of the most important therapeutic modalities to clinically cure cancer patients 1, 2, 3.The fundamental mechanisms of antibody-based cancer therapy include direct …

    DA: 58 PA: 29 MOZ Rank: 63

  • 2022年ASCO转移性乳腺癌的治疗进展

    cjco.cn

    http://www.cjco.cn/cn/article/doi/10.12354/j.issn.1000-8179.2023.20220959

    Web本文将就此次大会中有关转移性乳腺癌治疗的重要进展进行综述。. Abstract: Breast cancer studies presented at the 2022 ASCO meeting demonstrated several novel findings: improved survival prognosis in patients with low HER-2 expression with HER-2-targeted therapy, prolonged progression-free survival (PFS) with sacituzumab ...

    DA: 70 PA: 89 MOZ Rank: 71

  • Archive | Journal of Clinical Oncology - ASCO Publications

    ascopubs.org

    https://ascopubs.org/loi/jco

    WebAmerican Society of Clinical Oncology. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2024 American Society of Clinical Oncology

    DA: 84 PA: 1 MOZ Rank: 98